Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3

Conditions

Leukemia, Myeloid, Acute 49Neoplasm Metastasis 46Multiple Myeloma 40Breast Neoplasms 33Prostatic Neoplasms 30Colorectal Neoplasms 27Lymphoma 26Lung Neoplasms 26Leukemia, Lymphocytic, Chronic, B-Cell 24Pancreatic Neoplasms 23Myelodysplastic Syndromes 22Lymphoma, Large B-Cell, Diffuse 21Triple Negative Breast Neoplasms 19Ovarian Neoplasms 17Melanoma 17Carcinoma, Non-Small-Cell Lung 17Burkitt Lymphoma 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Neoplasms 15Carcinoma, Renal Cell 15Leukemia, Myelomonocytic, Chronic 13Glioma 13Neuroblastoma 12Lymphoma, Mantle-Cell 12Lymphoma, Follicular 12Sarcoma 11Lymphoma, Non-Hodgkin 11Fallopian Tube Neoplasms 11Endometrial Neoplasms 11Myeloproliferative Disorders 10

Interventions

Doxorubicin 5pembrolizumab 4Specimen Handling 4Radiotherapy 4Radiation 4Nivolumab 4Magnetic Resonance Spectroscopy 3Ipilimumab 3CTLA-4 Antigen 3Biopsy 3cabozantinib 2Ifosfamide 2tremelimumab 1talimogene laherparepvec 1regorafenib 1peposertib 1pazopanib 1olaratumab 1liposomal doxorubicin 1futibatinib 1fludarabine 1eribulin 1durvalumab 1avelumab 1aldesleukin 1X-Rays 1Trabectedin 1Standard of Care 1Quality of Life 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Histiocytoma, Malignant Fibrous × Biopsy × 1 year × Clear all
NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

National Cancer Institute (NCI)

Phase 1 Recruiting
30 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT02923778 2026-05-13

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

NCT05836571 2026-04-21

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
66 enrolled
Sarcoma

Sarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡